Form 4: NextCure Director Ellen Feigal Acquires Stock Options
SEC Form 4
Director Ellen Feigal acquired stock options in NextCure, Inc. on June 20, 2024.
Summary
- Ellen Feigal, a director of NextCure, Inc., acquired 18,700 stock options on June 20, 2024.
- The exercise price of these options is $1.5.
- The options vest fully on the earlier of June 20, 2025, and the date of the 2025 Annual Meeting of Stockholders.
- The expiration date for these options is June 19, 2034.
- Following the transaction, Ms. Feigal directly owns 18,700 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of earliest transaction and grant date of stock options. |
| 06/20/2025 | Vesting date of the stock options (or the date of the 2025 Annual Meeting of Stockholders, whichever is earlier). |
| 06/19/2034 | Expiration date of the stock options. |
| 06/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.